ABT

Abbott Laboratories

118.95

Top Statistics
Market Cap 206 B Forward PE 23.06 Revenue Growth 4.90 %
Current Ratio 1.60 Trailing PE 36.16 Earnings Growth 14.60 %
Profit Margins 13.99 % Peg Ratio Dividend Yield 1.85 %
Enterprice / EBITA 19.75 Enterprise / Revenue 5.19 Price To Sales Trailing12 Months 5.01
Profitability
Profit Margins 13.99 % Operating Margins 18.75 %
Balance Sheet
Total Cash 7 B Total Cash Per Share 4.49 Total Debt 15 B
Total Debt To Equity 37.59 Current Ratio 1.60 Book Value Per Share 22.94
All Measures
Return On Equity 0.1484 Total Debt 15 B Beta 0.7220
Last Split Date 1 B Fifty Two Week Low 99.71 Audit Risk 9
Target Mean Price 129.87 Short Percent Of Float 0.0070 Trailing Peg Ratio 230.97 %
Last Fiscal Year End 1 B Average Volume10days 5 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0053 Ebitda Margins 26.26 % Trailing PE 36.16
Most Recent Quarter 1 B Gmt Off Set Milliseconds -18000000 Fifty Day Average 115.66
Open 118.35 State IL Return On Assets 0.0649
Time Zone Short Name EST Board Risk 7 Trailing Eps 3.29
Day Low 118.10 Shares Outstanding 1 B Compensation Risk 9
Price Hint 2 Website https://www.abbott.com 52 Week Change 0.1406
Recommendation Key buy Quick Ratio 99.60 % Last Split Factor 10000:4798
Is_sp_500 True Profit Margins 13.99 % Debt To Equity 37.59
Fifty Two Week High 121.64 Enterprise To Revenue 5.19 Operating Cashflow 8 B
Five Year Avg Dividend Yield 165.00 % Market Cap 206 B Quote Type EQUITY
Industry Medical Devices Ex Dividend Date 1 B Overall Risk 7
Long Name Abbott Laboratories Current Ratio 1.60 Number Of Analyst Opinions 24
Governance Epoch Date 1 B Forward PE 23.06 Regular Market Volume 3 M
Short Ratio 217.00 % Message Board Id finmb_247483 Shares Short Prior Month 13 M
City North Chicago Uuid 5f9c82b0-139d-3f8f-b30c-efd7ee9ccdcf Previous Close 117.96
First Trade Date Epoch Utc 322 M Book Value 22.94 Volume 3 M
Price To Book 5.18 Total Cash Per Share 4.49 Total Revenue 41 B
Shares Short Previous Month Date 1 B Target Median Price 130.03 Max Age 86400
Recommendation Mean 1.78 Sand P52 Week Change 0.3133 Operating Margins 18.75 %
Last Dividend Value 0.5500 Net Income To Common 5 B Ask 119.60
Implied Shares Outstanding 1 B Average Daily Volume10 Day 5 M Total Cash 7 B
Revenue Per Share 23.68 Dividend Rate 2.20 Date Short Interest 1 B
Share Holder Rights Risk 2 Regular Market Previous Close 117.96 Target Low Price 104.00
Free Cashflow 6 B Dividend Yield 1.85 % Target High Price 149.00
Address1 100 Abbott Park Road Trailing Annual Dividend Rate 2.20 Average Volume 5 M
Earnings Quarterly Growth 14.60 % Forward Eps 5.16 Compensation As Of Epoch Date 1 B
Regular Market Day High 120.53 Day High 120.53 Shares Short 12 M
Regular Market Open 118.35 Industry Key medical-devices Bid 118.49
Earnings Growth 14.60 % Revenue Growth 4.90 % Shares Percent Shares Out 0.0069
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Zip 60064-6400 Payout Ratio 65.65 % Regular Market Day Low 118.10
Held Percent Institutions 0.7764 Current Price 118.95 Address2 Abbott Park
Enterprise To Ebitda 19.75 Trailing Annual Dividend Yield 1.87 % Financial Currency USD
Gross Margins 55.91 % Industry Disp Medical Devices Country United States
Float Shares 1 B Two Hundred Day Average 110.93 Ir Website http://www.abbottinvestor.com/phoenix.zhtml?c=94004&p=irol-irhome
Enterprise Value 213 B Price To Sales Trailing12 Months 5.01 Last Dividend Date 1 B
Ebitda 10 B Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories.

In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders.

Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.